Meeting
2016 ASCO Annual Meeting
A phase 1B/ phase 2A study of TRC105 (Endoglin Antibody) in combination with pazopanib (P) in patients (pts) with advanced soft tissue sarcoma (STS).
Authors
Steven Attia
Mayo Clinic, Jacksonville, FL
Steven Attia , Kamalesh Kumar Sankhala , Richard F. Riedel , Steven Ian Robinson , Robert Martin Conry , Patrick McKay Boland , Minal A. Barve , Karen Fritchie , Ben K. Seon , Delia Alvarez , Bonne J. Adams , Ronald L. Shazer , Charles P. Theuer , Robert G. Maki
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT01975519
Citation
J Clin Oncol 34, 2016 (suppl; abstr 11016)
DOI
10.1200/JCO.2016.34.15_suppl.11016
Abstract #
11016
Poster Bd #
142
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with pazopanib in patients with advanced soft tissue sarcoma (STS).
First Author: Steven Attia
Poster
2023 ASCO Annual Meeting
A phase I study of nanoparticle albumin-bound sirolimus (NAB-S) combined with pazopanib (PAZO) in patients with advanced soft tissue sarcoma (STS).
First Author: Lee D. Cranmer
Poster
2020 ASCO Virtual Scientific Program
A randomized phase II study of MLN0128 (M) versus pazopanib (P) in patients (pt) with advanced sarcoma (Alliance A091304).
First Author: Matthew Ingham
Poster
2023 ASCO Annual Meeting
A phase 2a study evaluating the efficacy and safety of sutetinib in patients with advanced non–small-cell lung cancer (NSCLC) harboring uncommon EGFR mutations.
First Author: Fengying Wu